Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Innate Pharma (IPHA) Accounts Payables (2017 - 2025)

Historic Accounts Payables for Innate Pharma (IPHA) over the last 9 years, with Q2 2025 value amounting to $13.6 million.

  • Innate Pharma's Accounts Payables fell 2026.22% to $13.6 million in Q2 2025 from the same period last year, while for Jun 2025 it was $13.6 million, marking a year-over-year decrease of 2026.22%. This contributed to the annual value of $17.1 million for FY2024, which is 658.28% down from last year.
  • Per Innate Pharma's latest filing, its Accounts Payables stood at $13.6 million for Q2 2025, which was down 2026.22% from $17.1 million recorded in Q4 2024.
  • Innate Pharma's Accounts Payables' 5-year high stood at $32.7 million during Q4 2021, with a 5-year trough of $13.6 million in Q2 2025.
  • For the 5-year period, Innate Pharma's Accounts Payables averaged around $20.1 million, with its median value being $19.9 million (2022).
  • Per our database at Business Quant, Innate Pharma's Accounts Payables tumbled by 9992.28% in 2021 and then skyrocketed by 382.06% in 2023.
  • Quarter analysis of 5 years shows Innate Pharma's Accounts Payables stood at $32.7 million in 2021, then plummeted by 34.73% to $21.3 million in 2022, then decreased by 14.17% to $18.3 million in 2023, then dropped by 6.58% to $17.1 million in 2024, then decreased by 20.32% to $13.6 million in 2025.
  • Its Accounts Payables was $13.6 million in Q2 2025, compared to $17.1 million in Q4 2024 and $17.1 million in Q2 2024.